Latest News and Press Releases
Want to stay updated on the latest news?
-
November 19, 2021Announcement no. 23 In an effort to prioritize Emergency Use Authorizations (EUA), the FDA does not recommend that BioPorto pursue an EUA for its NGAL assay for the prediction of...
-
November 19, 2021Announcement no. 22New composition of the management board of BioPorto A/S With reference to announcement nos. 16 and 17 regarding the appointment of Anthony Pare and Neil A....
-
November 17, 2021Announcement no. 21Q3 2021 Report Highlights Revenue growth driven by antibodies and RUO sales of The NGAL Test In the first nine months of 2021, BioPorto’s revenue...
-
November 15, 2021Announcement no. 20 BioPorto A/S - Extraordinary General Meeting, New Board Member Today, BioPorto A/S held an Extraordinary General Meeting where Peter Mørch Eriksen was elected...
-
November 3, 2021Announcement no. 19 Update on Patient Enrollment for Pivotal Study of NGAL in Pediatrics COVID-19 has continued to impact hospital operations and BioPorto’s enrollment of pediatric...
-
October 22, 2021 Announcement no. 18 NOTICE CONVENING THE EXTRAORDINARY GENERAL MEETING With reference to company announcement no. 16, the Board of Directors hereby convenes an...
-
October 20, 2021Announcement no. 17 BioPorto A/S appoints new Chief Financial Officer BioPorto A/S (“BioPorto”) today announces the appointment of Neil A. Goldman, CPA as its new Executive Vice...
-
October 20, 2021Announcement no. 16 BioPorto A/S appoints new Chief Executive Officer and announces changes to the Board of Directors BioPorto A/S (“BioPorto”) has announced the appointment of...
-
August 31, 2021Announcement no. 15 BioPorto Successfully Completes Interim Analysis of Data from Pivotal Study of NGAL in Pediatrics with Encouraging Results BioPorto A/S (BioPorto) has successfully...
-
August 18, 2021Announcement no. 14Q2 2021 Report Highlights Solid revenue growth in the first half of 2021 In the first half of 2021, BioPorto’s revenue grew by 20% measured in USD and...